Blys levels in sera of patients with systemic lupus erythematosus: Clinical and serological correlation

Israel Medical Association Journal

Volumn 16, Issue 8, 2014, Pages 491-496

  Elbirt, Daniel ^a   Asher, Ilan ^a   Mahlab Guri, Keren ^a   Bezalel Rosenberg, Shira ^a   Edelstein, Victor ^b,c   Sthoeger, Zev ^a,b,c  

^a Dept of Allergy   (Israel)

^b KAPLAN MEDICAL CENTER   (Israel)

^c HEBREW UNIVERSITY   (Israel)

Author keywords

Anti ds DNA autoantibodies; BAFF; BLyS; Lupus pathogenesis; Systemic lupus erythematosus (SLE)

Indexed keywords

B CELL ACTIVATING FACTOR; DOUBLE STRANDED DNA ANTIBODY; ANTINUCLEAR ANTIBODY; AUTOANTIBODY;

ADULT; ARTICLE; B LYMPHOCYTE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FOLLOW UP; HUMAN; MALE; PROTEIN BLOOD LEVEL; SCORING SYSTEM; SLEDAI; SYSTEMIC LUPUS ERYTHEMATOSUS; AUTOIMMUNITY; BLOOD; CELL SURVIVAL; IMMUNE SYSTEM; IMMUNOLOGY; ISRAEL; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; PATIENT ACUITY; PHYSIOLOGY; STATISTICS;

ADULT; ANTIBODIES, ANTINUCLEAR; AUTOANTIBODIES; AUTOIMMUNITY; B-CELL ACTIVATING FACTOR; B-LYMPHOCYTES; CELL SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNE SYSTEM; ISRAEL; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; PATIENT ACUITY; STATISTICS AS TOPIC;

EID: 84907441858     PISSN: 15651088     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Rahman A, Isenberg DA. Systemic lupus erythematosus. N Engl J Med. 2008; 358: 929-39
2. Mok CC, Lau CS. Pathogenesis of systemic lupus erythematosus. J Clin Pathol 2003; 56: 481-90
3. Osnes LT, Nakken B, Bodolay E, Szodoray P. Assessment of intracellular cytokines and regulatory cells in patients with autoimmune diseases and primary immunodeficiencies – novel tool for diagnostics and patient follow-up. Autoimmun Rev 2013; 12 (10): 967-71
4. Lauwerys BR, Houssiau FA. Cytokines: clues to the pathogenesis of SLE. Lupus 1998; 7: 211-13
5. Moore PA, Belvedere O, Orr A, et al. BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator. Science 1999; 285: 260-3
6. Marsters SA, Yan M, Pitti RM, Haas PE, Dixit VM, Ashkenazi A. Interaction of the TNF homologues BLyS and APRIL with the TNF receptor homologues BCMA and TACI. Curr Biol 2000; 10: 785-8
7. Khare SD, Sarosi I, Xia X-Z, et al. Severe B cell hyperplasia and autoimmune disease in TALL-1 transgenic mice. Proc Natl Acad Sci USA 2000; 97: 3370–5
8. Stohl W, Xu D, Kim KS, et al. BAFF overexpression and accelerated glomerular disease in mice with an incomplete genetic predisposition to systemic lupus erythematosus. Arthritis Rheum 2005; 52: 2080-91
9. Vincent FB, Northcott M, Hoi A, Mackay F, Morand EF. Association of serum B cell activating factor from the tumour necrosis factor family (BAFF) and a proliferation-inducing ligand (APRIL) with central nervous system and renal disease in systemic lupus erythematosus. Lupus 2013; 22 (9): 873-84
10. Cheema GS, Roschke V, Hilbert DM, Stohl W. Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases. Arthritis Rheum 2001; 44: 1313-19
11. Collins CE, Gavin AL, Migone TS, Hilbert DM, Nemazee D, Stohl W. B lymphocyte stimulator (BLyS) isoforms in systemic lupus erythematosus: disease activity correlates better with blood leukocyte BLyS mRNA levels than with plasma BLyS protein levels. Arthritis Res Ther 2006; 8: R6
12. Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271-7
13. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang DH, and the Committee on Prognosis Studies in SLE. Derivation of the SLEDAI: a disease activity index for lupus patients. Arthritis Rheum 1992; 35: 630-40
14. Petri M, Stohl W, Chatham W, et al. Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus. Arthritis Rheum 2008; 58: 2453-9
15. Stohl W. B lymphocyte stimulator protein levels in systemic lupus erythematosus and other diseases. Curr Rheumatol Rep 2002; 4: 345-50
16. Stohl W, Metyas S, Tan SM, et al. B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: longitudinal observations. Arthritis Rheum 2003; 48: 3475-86
17. Cancro MP, D’Cruz DP, Khamashta MA. The role of B lymphocyte stimulator (BLyS) in systemic lupus erythematosus. J Clin Invest 2009; 119: 1066-73
18. Stohl W. Systemic lupus erythematosus and its ABCs (APRIL/BLyS complexes). Arthritis Res Ther 2010; 12: 111
19. Ju S, Zhang D, Wang Y, Ni H, Kong X, Zhong R. Correlation of the expression levels of BLyS and its receptors mRNA in patients with systemic lupus erythematosus. Clin Biochem 2006; 39: 1131-7
20. Hong SD, Reiff A, Yang HT, et al. B lymphocyte stimulator expression in pediatric systemic lupus erythematosus and juvenile idiopathic arthritis patients. Arthritis Rheum 2009; 60: 3400-9
21. Bezalel S, Asher I, Elbirt D, Sthoeger ZM. Novel biological treatments for systemic lupus erythematosus: current and future modalities. IMAJ 2012; 14 (8): 508-14
22. Sthoeger ZM, Chiorazzi N, Lahita RG. Regulation of immune response by sex hormones. I. In vivo effects of estradiol and testosterone on pokeweed mitogen-induced human B cell differentiation. J Immunol 1988; 141: 91-8
23. Toubi E, Kessel A, Rosner I, Rozenbaum M, Paran D, Shoenfeld Y. The reduction of serum B-lymphocyte activating factor levels following quinacrine add-on therapy in systemic lupus erythematosus. Scand J Immunol 2006; 63: 299-303
24. Hahn BH. Belimumab for systemic lupus erythematosus. N Engl J Med 2013; 368: 1528-35
25. Toubi E, Shoenfeld Y. BLyS/BAFF: a potential target in the treatment of active systemic lupus erythematosus. IMAJ 2004; 6: 99-102